Treatment alternatives for Mycobacterium kansasii

被引：6

作者：

Graybill, JR

Bocanegra, R

机构：

[1] Vet Adm Hosp, Infect Dis Serv, San Antonio, TX 78284 USA

[2] Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2001年 / 47卷 / 04期

关键词：

D O I：

10.1093/jac/47.4.417

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Mycobacterium kansasii was administered intravenously to congenitally athymic (nude) mice. Beginning 1 week later, rifapentine, azithromycin, ethambutol or combined therapy was initiated orally. All three drugs were highly active individually. Although there was no evidence of antagonism, combined therapy was not more effective than either component used alone.

引用

收藏

页码：417 / 420

页数：4

相关论文

共 9 条

[1] INVITRO SUSCEPTIBILITY OF MYCOBACTERIUM-KANSASII TO CLARITHROMYCIN [J].

BIEHLE, J ;

CAVALIERI, SJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (09) :2039-2041

[2] ACTIVITIES OF CLARITHROMYCIN AGAINST 8 SLOWLY GROWING SPECIES OF NONTUBERCULOUS MYCOBACTERIA, DETERMINED BY USING A BROTH MICRODILUTION MIC SYSTEM [J].

BROWN, BA ;

WALLACE, RJ ;

ONYI, GO .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (09) :1987-1990

[3] THE EPIDEMIOLOGY OF DISSEMINATED NONTUBERCULOUS MYCOBACTERIAL INFECTION IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) [J].

HORSBURGH, CR ;

SELIK, RM .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1989, 139 (01) :4-7

[4] ACTIVITIES OF AZITHROMYCIN AND CLARITHROMYCIN AGAINST NONTUBERCULOUS MYCOBACTERIA IN BEIGE MICE [J].

KLEMENS, SP ;

CYNAMON, MH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (07) :1455-1459

[5] Species distribution in human immunodeficiency virus-related mycobacterial infections: Implications for selection of initial treatment [J].

Montessori, V ;

Phillips, P ;

Montaner, J ;

Haley, L ;

Craib, K ;

Bessuille, E ;

Black, W .

CLINICAL INFECTIOUS DISEASES, 1996, 22 (06) :989-992

[6] MYCOBACTERIUM-KANSASII BACTEREMIA IN PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS [J].

PARENTI, DM ;

SYMINGTON, JS ;

KEISER, J ;

SIMON, GL .

CLINICAL INFECTIOUS DISEASES, 1995, 21 (04) :1001-1003

[7] ACTIVITIES OF SPARFLOXACIN, AZITHROMYCIN, TEMAFLOXACIN, AND RIFAPENTINE COMPARED WITH THAT OF CLARITHROMYCIN AGAINST MULTIPLICATION OF MYCOBACTERIUM-AVIUM COMPLEX WITHIN HUMAN MACROPHAGES [J].

PERRONNE, C ;

GIKAS, A ;

TRUFFOTPERNOT, C ;

GROSSET, J ;

VILDE, JL ;

POCIDALO, JJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (07) :1356-1359

[8] RIFAMPIN-RESISTANT MYCOBACTERIUM-KANSASII [J].

WALLACE, RJ ;

DUNBAR, D ;

BROWN, BA ;

ONYI, G ;

DUNLAP, R ;

AHN, CH ;

MURPHY, DT .

CLINICAL INFECTIOUS DISEASES, 1994, 18 (05) :736-743

[9] SUSCEPTIBILITY OF MYCOBACTERIUM-KANSASII TO OFLOXACIN, SPARFLOXACIN, CLARITHROMYCIN, AZITHROMYCIN, AND FUSIDIC ACID [J].

WITZIG, RS ;

FRANZBLAU, SG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (09) :1997-1999